Association of TP53 codon 72 and CDH1 genetic polymorphisms with colorectal cancer risk in Bangladeshi population |
| |
| Affiliation: | 1. Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh;2. Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh;3. Pharmacogenetics Lab, Labaid Limited, Dhaka, Bangladesh;4. Department of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali 3814, Bangladesh;1. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States;2. Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, United States;3. Children''s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, United States;4. Institutional Research and Reporting, Salt Lake Community College, Salt Lake City, UT 84123, United States;5. Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 77555, United States;1. University of Hawaii Cancer Center, Honolulu, HI, 9613, USA;2. CESP Inserm, Villejuif, France;3. Gustave Roussy, Villejuif, F-94805, France;4. Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia;5. Department of Clinical and Experimental Medicine, University of Pisa, Italy;1. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, United States;2. Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Utah School of Medicine, Salt Lake City, UT 84113, United States;3. Department of Institutional Research and Reporting, Salt Lake Community College, Salt Lake City, UT 84123, United States;4. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555, United States;5. Department of Pediatric Hematology/Oncology, Salt Lake City Primary Children’s Hospital, UT 84132, United States;6. Division of Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, United States;1. Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, DK-8000 Aarhus C, Denmark;2. University Clinic for Innovative Patient Pathways, Silkeborg Hospital, Department of Clinical Medicine, Aarhus University, Falkevej 1-3, DK-8600 Silkeborg, Denmark;1. Department of Epidemiology and Health Statistics, School of Public Health, Zhejiang University, Hangzhou, China;2. Group of Molecular Epidemiology & Cancer Precision Prevention (GMECPP), Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences (ZJAMS), Hangzhou, China;3. Xiamen Second Hospital, Xiamen, China;4. Jiashan Institute of Cancer Prevention and Treatment, Zhejiang Province, China;1. Research Unit for General Practice, Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark;2. Research Centre for Cancer Diagnosis in Primary Care, Department of Public Health, Aarhus University, Bartholins Allé 2, 8000 Aarhus C, Denmark;3. Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Falkevej 1-3, 8600 Silkeborg, Denmark;4. Cancer Epidemiology and Population Health, King’s College London, Great Maze Pond, London SE1 9RT, United Kingdom |
| |
| Abstract: | Till now no pharmacogenetic study of TP53 codon 72 (Arg72Pro) and CDH1 rs16260 (-160CTP53 codon 72 and CDH1 rs16260 genetic polymorphism in Bangladeshi population for the first time. To investigate the association of these two SNPs, we conducted a case-control study with 288 colorectal cancer patients and 295 healthy volunteers by using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. We found an increased risk of association between Arg/Pro heterozygosity (adjusted OR = 2.58, 95% CI = 1.77–3.77, p < 0.05) and Pro/Pro mutant homozygosity (adjusted OR = 2.92, 95% CI = 1.78–4.78, p < 0.05) along with the combined genotype (Arg/Pro + Pro/Pro) (adjusted OR = 2.70, 95% CI = 1.90–3.82, p < 0.05) and colorectal cancer predisposition. In case of CDH1 rs16260 polymorphism, C/A heterozygous and A/A mutant homozygous are significantly (p < 0.05) found to be associated with colorectal cancer risk with adjusted OR of 1.94 and 2.63, respectively. The combined genotype of C/A and A/A was also found to be strongly associated with colorectal cancer risk compared to C/C genotype (adjusted OR = 2.02, 95% CI = 1.42–2.87, p < 0.05). In conclusion, heterozygosity and mutant homozygosity as well as the combination of both TP53 Arg72Pro and CDH1 rs16260 polymorphisms are responsible to increase the risk of colorectal cancer development in Bangladeshi population. |
| |
| Keywords: | Colorectal cancer Genetic polymorphisms Bangladeshi population |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
